AbbVie's PARP fails in Phase III NSCLC, TNBC trials

AbbVie Inc. (NYSE:ABBV) said veliparib (ABT-888) missed the primary endpoints in two Phase III studies to treat non-small cell lung cancer and early-stage triple-negative breast cancer. The company announced the news after market close.

In the NSCLC study, veliparib failed to significantly improve overall survival (OS) vs. placebo in patients who last smoked within 12 months and had more than 100 lifetime smoking events. The 970-patient trial evaluated carboplatin and paclitaxel plus veliparib or placebo in patients with previously untreated metastatic or advanced squamous NSCLC. ...